Product Description
Phenprocoumon is a derivative of coumarin, used as a preventative anticoagulant and in the treatment of thromboembolisms. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19409836/)
Mechanisms of Action: Vitamin K Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Brazil | Denmark | Germany | Italy | Luxembourg | Netherlands | Switzerland | United Kingdom
Approved Indications: None
Known Adverse Events: None
Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 4: Atrial Fibrillation|Acute Coronary Syndrome|Thromboembolism|Coronary Artery Disease|Embolism|Pulmonary Embolism|Myocardial Ischemia|Thrombosis|Atherosclerosis
Phase 2: Atrial Fibrillation|Thrombosis|Atrial Flutter
Phase 1: Melanoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| ReLoaDeD | N/A |
Completed |
Atrial Fibrillation |
2019-12-10 |
|
| RE-LATED-AF | P2 |
Terminated |
Atrial Fibrillation |
2018-05-22 |
|
| RE-LATED_AF | P2 |
Terminated |
Thrombosis|Atrial Flutter|Atrial Fibrillation |
2018-05-01 |
|
| BI 1160.206 | P4 |
Unknown status |
Atrial Fibrillation|Thrombosis |
2017-12-01 |